Search

Your search keyword '"van de Loosdrecht, Arjan A."' showing total 927 results

Search Constraints

Start Over You searched for: Author "van de Loosdrecht, Arjan A." Remove constraint Author: "van de Loosdrecht, Arjan A."
927 results on '"van de Loosdrecht, Arjan A."'

Search Results

3. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

6. Molecular taxonomy of myelodysplastic syndromes and its clinical implications

7. Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium

9. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

10. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

11. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

12. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

13. The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

15. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

18. Guideline-based indicators for adult patients with myelodysplastic syndromes

19. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML

21. Morphology and Flow Cytometry

22. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

24. TCF4 promotes erythroid development

26. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

27. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning

28. P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE

29. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.

30. P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML

31. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

33. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

34. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

35. Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes

38. Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes

42. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

43. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

46. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

47. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

48. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

49. Time-dependent changes in mortality and transformation risk in MDS

Catalog

Books, media, physical & digital resources